Merus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth Potential

Merus N.V. (NASDAQ:MRUS) ranks among the best biotech stocks to buy. On September 17, Barclays began coverage of Merus N.V. (NASDAQ:MRUS) with a price target of $112 and an Overweight rating. Barclays pointed out that the approval of zenocutuzumab for rare malignancies has commercially validated Merus’s platform.

Source: Pixabay

According to Barclays, Merus’s Phase 3 clinical asset, petosemtamab, is being investigated through two potentially registration-enabling Phase 3 trials for frontline and previously treated metastatic head and neck cancers.

With petosemtamab undergoing clinical derisking in head and neck malignancies and possible value creation in colorectal cancer through year-end 2026, the firm sees a substantial opportunity for share gain.

Merus NV is a biotechnology company that develops antibody-based cancer treatments. It has several initiatives in the works, including Zenocutuzumab and Petosemtamab (MCLA-158).

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

This article is originally published at Insider Monkey.